学习经历

1995－1999  北京大学生命科学学院，本科生，获学士学位

1999－2004  北京大学生命科学学院，硕博连读研究生，获博士学位

2001－2002  美国国立犹太医学研究中心，交换学生

主要工作经历与任职情况

2004－2007  耶鲁大学医学院，博士后

2007－2009  美国Stowers医学研究所，博士后

2009-至今     武汉大学生命科学学院，教授，博士生导师

2021-至今     武汉大学生命科学学院生物化学系主任

主要社会兼职

2015-至今  中国生物化学与分子生物学会基因专业委员会委员

2016-至今  中国细胞生物学会染色质生物学分会委员

2017-至今  湖北省细胞生物学会理事

2021-至今  中国医药生物技术协会疾病模型专业委员会委员

主要科研奖励和个人荣誉

2022 乳腺癌基因诊断指导精准治疗关键技术创新与应用，湖北省科技进步二等奖，第四完成人

2016 武汉大学生命科学学院“双一流”特聘教授

2010 细胞凋亡与抗病毒反应的信号转导研究，国家自然科学二等奖，第四完成人

2010 湖北省“楚天学者”计划楚天学子教授

2006 北京大学优秀博士论文二等奖

2006 细胞凋亡与NF-kappaB激活的信号传导研究，教育部科学技术奖一等奖，第四完成人

研究内容

致力于癌症发生发展过程中表观遗传调控机制的研究，利用表观遗传组和转录组等多组学分析以及细胞分子生物学的方法，阐明了在乳腺癌和结直肠癌中特异增强子的基因组图谱及其调控机制，发现异染色质异常可以诱导核DNA和组蛋白转运到细胞质并激活天然免疫信号通路，揭示组蛋白甲基化H3K36甲基化修饰及其蛋白酶SETD2在癌症发生发展过程中的作用及其调控机制。

主持课题项目

1. 国家自然科学基金面上项目，81972647，转录增强子活性变化在乳腺癌发生发展过程中的作用和分子调控机制，2020.01-2023.12，55万元，在研，项目负责人；

2. 国家自然科学基金面上项目，31771503，泛素E3连接酶SPOP/CUL3/RBX1复合物调控肿瘤发生的分子机制，2018.1-2021.12，60万元，在研，项目负责人；

3. 湖北省技术创新专项重大项目，2017ACA095，基于高通量测序的结肠癌精准医疗检测和药物开发关键技术，2017.6-2020.6，165万元，在研，项目负责人

4. 国家重点研发计划，2016YFA0502100，疱疹病毒感染和致病过程中蛋白质机器的功能机制，2016.7-2021.6，320万元，在研，课题组长；

5. 国家自然科学基金面上项目，31470771，组蛋白甲基化酶SETD2调控肿瘤发生的分子机制研究，2015.1-2018.12，85万元，结题，主持；

6. 国家科技部973项目，2012CB518700，重要病原菌与宿主相互作用分子机制的研究，2012.1-2016.12，100万元，结题，学术骨干；

7. 国家科技部973项目，2011CB504200，恶性肿瘤发生、发展的细胞表观遗传机制，2011.1-2015.12，180.4万元，结题，学术骨干；

8. 教育部新世纪优秀人才支持计划，NCET-11-0410，教育部新世纪优秀人才支持计划，2012.1-2014.12，50万元，结题，主持；

9. 国家自然科学基金重大研究计划“细胞编程与重编程表观遗传机制”培育项目，91019013，组蛋白H3K4甲基化建立、维持和调控NF-κB信号途径的分子机制研究，2011.1-2013.12，60万元，结题，主持；

10. 国家自然科学基金面上项目，30971502，甲基化酶SMYD2调节p53信号途径的机制的研究，2010.1-2012.12，31万元，结题，主持。

发表的论文（^#并列第一作者，^*通讯作者）

1. Xiao, Q., Wang, C.Y., Gao, C., Chen, J.D., Chen, J.J., Wang, Z., Ju, L.G., Tang, S.B., Yao, J., Li, F., Li, L.Y., and Wu, M.*, Regulation of KDM5C stability and enhancer reprogramming in breast cancer. Cell Death Dis, 2022. 13(10): p. 843.

2. Xiao, Q., Xiao, Y., Li, L.Y., Chen, M.K.*, and Wu, M.*, Multifaceted regulation of enhancers in cancer. Biochim Biophys Acta Gene Regul Mech, 2022. 1865(6): p. 194839.

3. Chen, L., Yang, C., Tang, S.-B., Long, Q.-Y., Chen, J.-D., Wu, M.*, and Li, L.-Y.*, Inhibition of histone methyltransferase SETD8 represses DNA virus replication. Cell Insight, 2022. 1(3).

4. Chen, L., Luo, Z., Zhao, C., Li, Q., Geng, Y., Xiao, Y., Chen, M.K., Li, L., Chen, Z.X.*, and Wu, M.*, Dynamic Chromatin States Coupling with Key Transcription Factors in Colitis-Associated Colorectal Cancer. Adv Sci (Weinh), 2022: p. e2200536.

5. Li, Q.L., Lin, X., Yu, Y.L., Chen, L., Hu, Q.X., Chen, M., Cao, N., Zhao, C., Wang, C.Y., Huang, C.W., Li, L.Y., Ye, M. *, and Wu, M. *, Genome-wide profiling in colorectal cancer identifies PHF19 and TBC1D16 as oncogenic super enhancers. Nat Commun, 2021. 12(1): p. 6407.

6. Hu, Q.X., Wang, H.Y., Jiang, L., Wang, C.Y., Ju, L.G., Zhu, Y., Zhong, B., Wu, M. *, Wang, Z. *, and Li, L.Y. *, Histone demethylase LSD1 promotes RIG-I poly-ubiquitination and anti-viral gene expression. PLoS Pathog, 2021. 17(9): p. e1009918.

7. Wang, Z., Chen, J., Gao, C., Xiao, Q., Wang, X.W., Tang, S.B., Li, Q.L., Zhong, B., Song, Z.Y., Shu, H.B., Li, L.Y., and Wu, M. *, Epigenetic Dysregulation Induces Translocation of Histone H3 into Cytoplasm. Adv Sci (Weinh), 2021: p. e2100779.

8. Wang, C.Y., Yu, G.T., Gao, C., Chen, J., Li, Q.L., Zhang, L., Wu, M. *, Sun, Z.J. *, and Li, L.Y. *, Genome-Wide Enhancer Analysis Reveals the Role of AP-1 Transcription Factor in Head and Neck Squamous Cell Carcinoma. Front Mol Biosci, 2021. 8: p. 701531.

9. Zheng, J.Y., Wang, C.Y., Gao, C., Xiao, Q., Huang, C.W., Wu, M. *, and Li, L.Y. *, MLL3 suppresses tumorigenesis through regulating TNS3 enhancer activity. Cell Death Dis, 2021. 12(4): p. 364.

10. Xu, L., Zheng, Y., Li, X., Wang, A., Huo, D., Li, Q., Wang, S., Luo, Z., Liu, Y., Xu, F., Wu, X., Wu, M. *, and Zhou, Y. *, Abnormal neocortex arealization and Sotos-like syndrome-associated behavior in Setd2 mutant mice. Sci Adv, 2021. 7(1).

11. Li, X.J., Li, Q.L., Ju, L.G., Zhao, C., Zhao, L.S., Du, J.W., Wang, Y., Zheng, L., Song, B.L., Li, L.Y., Li, L. *, and Wu, M. *, Deficiency of Histone Methyltransferase SET Domain-Containing 2 in Liver Leads to Abnormal Lipid Metabolism and HCC. Hepatology, 2021. 73(5): p. 1797-1815.

12. Yao J., Lei P.J., Li Q.L., Chen J., Tang S.B., Xiao Q., Lin X., Wang X., Li L.Y., Wu M.* GLIS2 promotes colorectal cancer through repressing enhancer activation. Oncogenesis 2020, 9:57.

13. Gao C., Chen L., Tang S.B., Long Q.Y., He J.L., Zhang N.A., Shu H.B., Chen Z.X., Wu M.*, Li L.Y.* The epigenetic landscapes of histone modifications on HSV-1 genome in human THP-1 cells. Antiviral Res 2020, 176:104730.

14. Wang H.Y., Long Q.Y., Tang S.B., Xiao Q., Gao C., Zhao Q.Y., Li Q.L., Ye M., Zhang L., Li L.Y., Wu M.* Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer. Nucleic Acids Res 2019, 47:2349-2364.

15. Li Q.L., Wang D.Y., Ju L.G., Yao J., Gao C., Lei P.J., Li L.Y., Zhao X.L.*, Wu M.* The hyper-activation of transcriptional enhancers in breast cancer. Clin Epigenetics 2019, 11:48.

16. Ju L.G., Zhu Y., Long Q.Y., Li X.J., Lin X., Tang S.B., Yin L., Xiao Y., Wang X.H., Li L., Zhang L., Wu M.* SPOP suppresses prostate cancer through regulation of CYCLIN E1 stability. Cell Death Differ 2019, 26:1156-1168.

17. 王震，李联运*，吴旻*。表观遗传相关药物对癌症的治疗。细胞生物学报，2018;40(8):1253-1263.

18. Zhu K., Lei P.J., Ju L.G., Wang X., Huang K., Yang B., Shao C., Zhu Y., Wei G., Fu X.D., Li L., Wu M.* SPOP-containing complex regulates SETD2 stability and H3K36me3-coupled alternative splicing. Nucleic Acids Res 2017, 45:92-105.

19. Wang Z., Long Q.Y., Chen L., Fan J.D., Wang Z.N., Li L.Y.*, Wu M.*, Chen X.* Inhibition of H3K4 demethylation induces autophagy in cancer cell lines. Biochim Biophys Acta 2017, 1864:2428-2437.

20. Li Q.L., Lei P.J., Zhao Q.Y., Li L., Wei G.*, Wu M.* Epigenomic analysis in a cell-based model reveals the roles of H3K9me3 in breast cancer transformation. Epigenomics 2017, 9:1077-1092.

21. Ju L.G., Zhu Y., Lei P.J., Yan D., Zhu K., Wang X., Li Q.L., Li X.J., Chen J.W., Li L.Y.*, Wu M.* TTLL12 Inhibits the Activation of Cellular Antiviral Signaling through Interaction with VISA/MAVS. J Immunol 2017, 198:1274-1284.

22. Jia X., Long Q., Miron R.J., Yin C., Wei Y., Zhang Y.*, Wu M.* Setd2 is associated with strontium-induced bone regeneration. Acta Biomater 2017, 53:495-505.

23. Zhao Q.Y., Lei P.J., Zhang X., Zheng J.Y., Wang H.Y., Zhao J., Li Y.M., Ye M., Li L., Wei G.*, Wu M.* Global histone modification profiling reveals the epigenomic dynamics during malignant transformation in a four-stage breast cancer model. Clin Epigenetics 2016, 8:34.

24. Su S.K., Li C.Y., Lei P.J., Wang X., Zhao Q.Y., Cai Y., Wang Z., Li L.*, Wu M.* The EZH1-SUZ12 complex positively regulates the transcription of NF-kappaB target genes through interaction with UXT. J Cell Sci 2016, 129:2343-2353.

25. Zhu K., Wang X., Ju L.G., Zhu Y., Yao J., Wang Y., Wu M.*, Li L.Y.* WDR82 Negatively Regulates Cellular Antiviral Response by Mediating TRAF3 Polyubiquitination in Multiple Cell Lines. J Immunol 2015, 195:5358-5366.

26. Fan J.D., Lei P.J., Zheng J.Y., Wang X., Li S., Liu H., He Y.L., Wang Z.N., Wei G., Zhang X., Li L.Y.*, Wu M.* The selective activation of p53 target genes regulated by SMYD2 in BIX-01294 induced autophagy-related cell death. PLoS One 2015, 10:e0116782.

27. Wang X., Ju L., Fan J., Zhu Y., Liu X., Zhu K., Wu M.*, Li L.* Histone H3K4 methyltransferase Mll1 regulates protein glycosylation and tunicamycin-induced apoptosis through transcriptional regulation. Biochim Biophys Acta 2014, 1843:2592-2602.

28. Zhao Q., Fan J., Hong W., Li L., Wu M.* Inhibition of cancer cell proliferation by 5-fluoro-2'-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway. Springerplus 2012, 1:65.

29. Wang X., Zhu K., Li S., Liao Y., Du R., Zhang X., Shu H.B., Guo A.Y., Li L.*, Wu M.* MLL1, a H3K4 methyltransferase, regulates the TNFalpha-stimulated activation of genes downstream of NF-kappaB. J Cell Sci 2012, 125:4058-4066.

30. Wu M.*, Shu H.B.* MLL1/WDR5 complex in leukemogenesis and epigenetic regulation. Chin J Cancer 2011, 30:240-246.

31. Wu M. ^#, Wang P.F.^#, Lee J.S., Martin-Brown S., Florens L., Washburn M., Shilatifard A. Molecular regulation of H3K4 trimethylation by Wdr82, a component of human Set1/COMPASS. Mol Cell Biol 2008, 28:7337-7344.

32. Higa L.A. ^#, Wu M. ^#, Ye T., Kobayashi R., Sun H., Zhang H. CUL4-DDB1 ubiquitin ligase interacts with multiple WD40-repeat proteins and regulates histone methylation. Nat Cell Biol 2006, 8:1277-1283.

33. Banks D. ^#, Wu M. ^#, Higa L.A., Gavrilova N., Quan J., Ye T., Kobayashi R., Sun H., Zhang H. L2DTL/CDT2 and PCNA interact with p53 and regulate p53 polyubiquitination and protein stability through MDM2 and CUL4A/DDB1 complexes. Cell Cycle 2006, 5:1719-1729.

34. Wu M. ^#, Xu L.G., Su T., Tian Y., Zhai Z., Shu H.B. AMID is a p53-inducible gene downregulated in tumors. Oncogene 2004, 23:6815-6819.

35. Wu M. ^#, Xu L.G., Zhai Z., Shu H.B. SINK is a p65-interacting negative regulator of NF-kappaB-dependent transcription. J Biol Chem 2003, 278:27072-27079.

36. Xu L.G. ^#, Wu M. ^#, Hu J., Zhai Z., Shu H.B. Identification of downstream genes up-regulated by the tumor necrosis factor family member TALL-1. J Leukoc Biol 2002, 72:410-416.

37. Wu M.^#, Xu L.G.^#, Li X., Zhai Z., Shu H.B. AMID, an apoptosis-inducing factor-homologous mitochondrion-associated protein, induces caspase-independent apoptosis. J Biol Chem 2002, 277:25617-25623.